Based on the WuXi AppTec Co. Ltd stock forecast from 0 analysts, the average analyst target price for WuXi AppTec Co. Ltd is not available over the next 12 months. WuXi AppTec Co. Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WuXi AppTec Co. Ltd is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, WuXi AppTec Co. Ltd’s stock price was EUR 4.30. WuXi AppTec Co. Ltd’s stock price has changed by +16.22% over the past week, +10.82% over the past month and -54.50% over the last year.
No recent analyst target price found for WuXi AppTec Co. Ltd
No recent average analyst rating found for WuXi AppTec Co. Ltd
Company Overview WuXi AppTec Co. Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; and drug discovery services to pharmaceutical and biotech customers. In addition, the company offers consulting services for combinatorial chemistry and pharmaceuticals; and develops computer software and databases. Further, it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China. Read Less
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The...Read More
Frequently Asked Questions About WuXi AppTec Co. Ltd (WX8:F) Stock
Stock Target Advisor's fundamental analysis for WuXi AppTec Co. Ltd's stock is Bullish .
WX8:F stock's dividend yield is 24.32%.
Our analysis grades WX8:F stock's dividend yield at A+. This means that WX8:F stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this WX8:F may be a good dividend stock for its sector.
Unfortunately we do not have enough data on WX8:F's stock to indicate what its average analyst target is.
WX8:F stock's Price/Earning ratio is 1.47.
Our analysis grades WX8:F stock's Price / Earning ratio at A+. This means that WX8:F stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this WX8:F may be undervalued for its sector.
The last closing price of WX8:F's stock was EUR 4.30.
The most recent market capitalization for WX8:F is EUR 113.71B.
Unfortunately we do not have enough analyst data on WX8:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WuXi AppTec Co. Ltd's stock.
As per our most recent records WuXi AppTec Co. Ltd has 38,134 Employees.
WuXi AppTec Co. Ltd's registered address is 288 Fute Zhong Road, Shanghai, China, 200131.
You can get more information about it from WuXi AppTec Co. Ltd's website at https://www.wuxiapptec.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About WuXi AppTec Co. Ltd (WX8:F) Stock
Stock Target Advisor's fundamental analysis for WuXi AppTec Co. Ltd's stock is Bullish .
WX8:F stock's dividend yield is 24.32%.
Our analysis grades WX8:F stock's dividend yield at A+. This means that WX8:F stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this WX8:F may be a good dividend stock for its sector.
Unfortunately we do not have enough data on WX8:F's stock to indicate what its average analyst target is.
WX8:F stock's Price/Earning ratio is 1.47.
Our analysis grades WX8:F stock's Price / Earning ratio at A+. This means that WX8:F stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Diagnostics & Research sector in the F exchange.
Based on this WX8:F may be undervalued for its sector.
The last closing price of WX8:F's stock was EUR 4.30.
The most recent market capitalization for WX8:F is EUR 113.71B.
Unfortunately we do not have enough analyst data on WX8:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WuXi AppTec Co. Ltd's stock.
As per our most recent records WuXi AppTec Co. Ltd has 38,134 Employees.
WuXi AppTec Co. Ltd's registered address is 288 Fute Zhong Road, Shanghai, China, 200131.
You can get more information about it from WuXi AppTec Co. Ltd's website at https://www.wuxiapptec.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WX8:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
